Semnur Pharmaceuticals has completed a Phase 3 study for the treatment of lumbar radicular pain, commonly known as sciatica meeting primary and important key secondary endpoints and has received fast track status from the FDA for the novel injectable gel formulation (SP-102) in development. Learn more
